SCHEMBL12465836

SCHEMBL12465836

COC(OC)C(C)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.44
GAA P10253 2/20 0.43
GBA1 P04062 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA3 P07451 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
ALDH1A1 P00352 8/20 0.40
VDR P11473 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16344743 0.87 TLR9 (0.45) TLR9GAAGBA1CA1CA2
SCHEMBL2342945 0.86 GAA (0.52) TLR9GAAGBA1CA1CA2
SCHEMBL5557903 0.86 GAA (0.52) TLR9GAAGBA1CA1CA2
SCHEMBL3521316 0.83 GAA (0.45) TLR9GAAGBA1CA1CA2
SCHEMBL1629581 0.82 TLR9 (0.48) TLR9GAAGBA1CA1CA2
SCHEMBL14778368 0.82 TLR9 (0.48) TLR9GAAGBA1CA1CA2
SCHEMBL14779302 0.81 TLR9 (0.47) TLR9GAAGBA1CA1CA2
SCHEMBL4969119 0.81 GAA (0.46) TLR9GAAGBA1CA1CA2
SCHEMBL890642 0.80 GAA (0.50) TLR9GAAGBA1CA1CA2
SCHEMBL143705 0.80 GAA (0.50) TLR9GAAGBA1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668162-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES Novartis AG (CH) 2013-12-04 EP disclosed
WO-2012101062-A1 SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES NOVARTIS AG (CH) 2012-08-02 WO disclosed